VEGFA and nonpapillary renal cell carcinoma: Based on the activity of lenvatinib (a multikinase inhibitor with predominant anti-VEGF activity) with everolimus in ccRCC following one line of VEGF-directed therapy, Hutson et al. evaluated the regimen in nccRCC [31,32].